经皮动静脉瘘项目开展初期结局与历史性手术动静脉瘘的比较
单中心回顾性研究比较Ellipsys经皮动静脉瘘(pAVF,24例)与手术BC-AVF(sAVF,62例)。pAVF组临床成熟率更低(52% vs 87%,P=0.003),主要失败率更高(39% vs 10%,P=0.003),术后干预率更高(78% vs 21%,P<0.001)。
要点
- pAVF临床成熟率低于sAVF(52% vs 87%,P=0.003)。
- pAVF主要失败率更高(39% vs 10%,P=0.003)。
- pAVF术后干预更频繁,吻合口旁段PTA最常见(57% vs 8%)。
核心结论
- 开展经皮动静脉瘘项目第一年内,Ellipsys pAVF的临床成熟率低于历史sAVF,且术后干预更多。
- 与既往Ellipsys数据的结果差异提示需进一步研究pAVF的实际可推广性。
研究设计与样本
- 单中心回顾性研究,pAVF组为2019年1月1日至12月31日连续Ellipsys经皮动静脉瘘患者24例。
- sAVF组为2018年1月1日至12月31日连续手术BC-AVF患者62例。
主要发现
- pAVF组与sAVF组平均手术时间相当(60±40 vs 56±25 min,P=0.67)。
- pAVF组与sAVF组技术成功率相当(23[96%] vs 62[100%],P=0.28)。
- pAVF组临床成熟率更低(12[52%] vs 54[87%],P=0.003)。
- pAVF组主要失败率更高(9[39%] vs 6[10%],P=0.003)。
- pAVF组总体术后干预率更高(18[78%] vs 13[21%],P<0.001),总干预次数更多(1.1±0.9 vs 0.3±0.6,P<0.001),吻合口旁段PTA更常见(13[57%] vs 5[8%],P<0.001)。
临床怎么用
- 开展pAVF项目初期应预期较低的临床成熟率和较高的术后干预需求。
- 需加强pAVF术后吻合口旁段狭窄的监测与干预规划。
局限性
- 单中心回顾性设计,pAVF与sAVF为不同年份的历史对照。
- 样本量较小(pAVF 24例,sAVF 62例)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Recently, there has been an abundance of encouraging data regarding the creation of percutaneous arteriovenous fistulas. Despite promising data regarding their clinical maturation, a paucity of data exists which provides direct comparison between percutaneously created AVFs (pAVF) and open surgically created AVFs (sAVF). This study has 2 primary objectives: First, to compare clinical outcomes of pAVFs to sAVFs, with emphasis on clinical maturation and frequency of postoperative interventions to facilitate maturation. Second, to contribute toward the evidence-based incorporation of the pAVF procedure into the hemodialysis access algorithm. METHODS: A single-center retrospective review was performed on all consecutive patients undergoing surgically created brachiocephalic arteriovenous fistula (BC-AVF, sAVF group) from January 1, 2018 to December 31, 2018 and Ellipsys-created percutaneous arteriovenous fistula (pAVF group) from January 1, 2019 to December 31, 2019. Comparative analysis between groups was performed. RESULTS: A total of 24 patients underwent Ellipsys-created pAVF with mean age of 56.7 ± 22.6 years (12 males [50%], 12 females [50%]) and 62 patients underwent surgically created BC-AVF with mean age of 62.5 ± 13.2 years (32 males [52%], 30 females [48%]). Both the pAVF and sAVF groups had comparable mean operating times (60 ± 40 vs. 56 ± 25 min, P = 0.67) and frequency of procedural technical success (23 [96%] vs. 62 [100%], P = 0.28), respectively. The pAVF group had a lower clinical maturation rate (12 [52%] vs. 54 [87%], P = 0.003) and a higher primary failure rate (9 [39%] vs. 6 [10%], P = 0.003) when compared to the sAVF group. The pAVF group had an increased overall rate of undergoing a postoperative intervention (18 [78%] vs. 13 [21%], P< 0.001), as well as an increased number of total postoperative interventions (1.1 ± 0.9 vs. 0.3 ± 0.6 interventions, P< 0.001) compared to the sAVF group. Percutaneous transluminal angioplasty of the juxta anastomotic segment was the most prevalent postoperative intervention performed in the pAVF group and occurred at a significantly increased frequency when compared to the sAVF group rate (13 [57%] vs. 5 [8%], P< 0.001). CONCLUSIONS: In our single-center retrospective review, patients undergoing Ellipsys-created pAVF in the first year following introduction of percutaneous endovascular had inferior rates of clinical maturation and underwent more postoperative interventions when compared to historical patients undergoing surgically created BC-AVF. Outcome discrepancies compared to previously reported Ellipsys data demonstrate a need for further studies examining the practical translatability of the pAVF.
引用
- Osofsky R, Byrd D, Reagor J, et al. Initial Outcomes Following Introduction of Percutaneous Arteriovenous Fistula Program with Comparison to Historical Surgically Created Fistulas. Ann Vasc Surg. 2021. PMID: 33549799. doi:10.1016/j.avsg.2020.12.041
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。